Juvenile Idiopathic Arthritis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examines DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB Pharma

Juvenile Idiopathic Arthritis Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examines DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB Pharma
The Juvenile Idiopathic Arthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Juvenile Idiopathic Arthritis pipeline products will significantly revolutionize the Juvenile Idiopathic Arthritis market dynamics.

DelveInsight’s “Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Juvenile Idiopathic Arthritis, historical and forecasted epidemiology as well as the Juvenile Idiopathic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Juvenile Idiopathic Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Juvenile Idiopathic Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Juvenile Idiopathic Arthritis Market Insight

 

Some of the key facts of the Juvenile Idiopathic Arthritis Market Report: 

  • The Juvenile Idiopathic Arthritis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogeneous disorders that manifests as joint inflammation in patients aged
  • According to the American College of Rheumatology (2022), approximately 1 child per 1,000 develops a form of chronic arthritis. While arthritis can impact children of any age, it is uncommon within the first six months of life. It is estimated that approximately 300,000 children in the United States have received a diagnosis of arthritis.
  • As per the National Institutes of Health (n.d.), Juvenile Idiopathic Arthritis (JIA) affects approximately 1 in every 1000 children in the United States. The most prevalent form of JIA in the country is oligoarticular juvenile idiopathic arthritis, constituting roughly half of all JIA cases.
  • According to the Pediatric Orthopedic Society of North America, Juvenile Idiopathic Arthritis (JIA) stands as the most prevalent chronic rheumatologic disorder in childhood. It registers an annual incidence ranging from 2 to 20 cases per 100,000 individuals, with a prevalence falling between 16 and 50 cases per 100,000 individuals. This equates to an estimated total of 294,000 affected children in the United States. Ethnicity can influence prevalence rates, with higher occurrences observed among northern Europeans.
  • Key Juvenile Idiopathic Arthritis Companies: Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
  • Key Juvenile Idiopathic Arthritis Therapies: Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
  • The Juvenile idiopathic arthritis epidemiology based on gender analyzed that according to Pediatric Rheumatology prevalence rate is consistently higher in girls in comparison to boys

 

Juvenile Idiopathic Arthritis Overview

Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function. 

 

Get a Free sample for the Juvenile Idiopathic Arthritis Market Report:

https://www.delveinsight.com/report-store/juvenile-idiopathic-arthritis-jia-market

 

Juvenile Idiopathic Arthritis Market  

The dynamics of the Juvenile Idiopathic Arthritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Juvenile Idiopathic Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Juvenile Idiopathic Arthritis Epidemiology Segmentation:

The Juvenile Idiopathic Arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Juvenile Idiopathic Arthritis
  • Prevalent Cases of Juvenile Idiopathic Arthritis by severity
  • Gender-specific Prevalence of Juvenile Idiopathic Arthritis
  • Diagnosed Cases of Episodic and Chronic Juvenile Idiopathic Arthritis

 

Download the report to understand which factors are driving Juvenile Idiopathic Arthritis epidemiology trends @ Juvenile Idiopathic Arthritis Epidemiological Insights

 

Juvenile Idiopathic Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Juvenile Idiopathic Arthritis market or expected to get launched during the study period. The analysis covers Juvenile Idiopathic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Juvenile Idiopathic Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Juvenile Idiopathic Arthritis Therapies and Key Companies

  • Sarilumab (Kevzara): Regeneron/Sanofi
  • Baricitinib: Eli Lilly and Company
  • Certolizumab pegol: UCB BIOSCIENCES GmbH
  • Upadacitinib: AbbVie
  • Tofacitinib: Pfizer
  • Sarilumab SAR153191 (REGN88): Sanofi
  • GenaKumab: Changchun GeneScience Pharma
  • AIN457: Novartis
  • Etanercept: Istituto Giannina Gaslini

 

To know more about Juvenile Idiopathic Arthritis treatment, visit @ Juvenile Idiopathic Arthritis Medications

 

Juvenile Idiopathic Arthritis Market Drivers

  • Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Juvenile Idiopathic Arthritis
  • Population rates of social anxiety disorder in children and young people have been investigated in several countries
  • Many therapies are under investigation in various phases of clinical trials

 

Juvenile Idiopathic Arthritis Market Unmet Needs

  • Challenge in recognition of condition
  • Development of novel therapies
  • Limited availability in services
  • Poor disease understanding
  • Development of effective treatment

 

Scope of the Juvenile Idiopathic Arthritis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Juvenile Idiopathic Arthritis Companies: Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
  • Key Juvenile Idiopathic Arthritis Therapies: Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
  • Juvenile Idiopathic Arthritis Therapeutic Assessment: Juvenile Idiopathic Arthritis current marketed and Juvenile Idiopathic Arthritis emerging therapies
  • Juvenile Idiopathic Arthritis Market Dynamics: Juvenile Idiopathic Arthritis market drivers and Juvenile Idiopathic Arthritis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Juvenile Idiopathic Arthritis Unmet Needs, KOL’s views, Analyst’s views, Juvenile Idiopathic Arthritis Market Access and Reimbursement 

 

Discover more about therapies set to grab major Juvenile Idiopathic Arthritis market share @ Juvenile Idiopathic Arthritis market forecast

 

Table of Contents 

1. Juvenile Idiopathic Arthritis Market Report Introduction

2. Executive Summary for Juvenile Idiopathic Arthritis

3. SWOT analysis of Juvenile Idiopathic Arthritis

4. Juvenile Idiopathic Arthritis Patient Share (%) Overview at a Glance

5. Juvenile Idiopathic Arthritis Market Overview at a Glance

6. Juvenile Idiopathic Arthritis Disease Background and Overview

7. Juvenile Idiopathic Arthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Juvenile Idiopathic Arthritis 

9. Juvenile Idiopathic Arthritis Current Treatment and Medical Practices

10. Juvenile Idiopathic Arthritis Unmet Needs

11. Juvenile Idiopathic Arthritis Emerging Therapies

12. Juvenile Idiopathic Arthritis Market Outlook

13. Country-Wise Juvenile Idiopathic Arthritis Market Analysis (2019–2032)

14. Juvenile Idiopathic Arthritis Market Access and Reimbursement of Therapies

15. Juvenile Idiopathic Arthritis Market Drivers

16. Juvenile Idiopathic Arthritis Market Barriers

17.  Juvenile Idiopathic Arthritis Appendix

18. Juvenile Idiopathic Arthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: